Condition
Ectasia Corneal
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Pxl 330 Platinum Deviceriboflavin
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Phase 2 (1)
Phase 2/3 (1)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Pxl 330 Platinum Deviceriboflavin1
- Riboflavin 011
Active Sponsors
- Price Vision Group1
- Eye Specialists of Indiana1
Top Investigators
Price Vision Group
Related Conditions
- Bacterial Keratitis1
- Keratoconus1
- Keratoconus Unstable1